Stock Research for SGEN

SGEN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

SGEN Stock Chart & Research Data

The SGEN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SGEN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


SGEN Due diligence Resources & Stock Charts

The SGEN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View SGEN Detailed Price Forecast - CNN Money CNN View SGEN Detailed Summary - Google Finance
Yahoo View SGEN Detailed Summary - Yahoo! Finance Zacks View SGEN Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View SGEN Trends & Analysis - Trade-Ideas Barrons View SGEN Major Holders - Barrons
NASDAQ View SGEN Call Transcripts - NASDAQ Seeking View SGEN Breaking News & Analysis - Seeking Alpha
Spotlight View SGEN Annual Report - CompanySpotlight.com OTC Report View SGEN OTC Short Report - OTCShortReport.com
TradeKing View SGEN Fundamentals - TradeKing Charts View SGEN SEC Filings - Bar Chart
WSJ View Historical Prices for SGEN - The WSJ Morningstar View Performance/Total Return for SGEN - Morningstar
MarketWatch View the Analyst Estimates for SGEN - MarketWatch CNBC View the Earnings History for SGEN - CNBC
StockMarketWatch View the SGEN Earnings - StockMarketWatch MacroAxis View SGEN Buy or Sell Recommendations - MacroAxis
Bullish View the SGEN Bullish Patterns - American Bulls Short Pains View SGEN Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View SGEN Stock Mentions - StockTwits PennyStocks View SGEN Stock Mentions - PennyStockTweets
Twitter View SGEN Stock Mentions - Twitter Invest Hub View SGEN Investment Forum News - Investor Hub
Yahoo View SGEN Stock Mentions - Yahoo! Message Board Seeking Alpha View SGEN Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for SGEN - SECform4.com Insider Cow View Insider Transactions for SGEN - Insider Cow
CNBC View SGEN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for SGEN - OTC Markets
Yahoo View Insider Transactions for SGEN - Yahoo! Finance NASDAQ View Institutional Holdings for SGEN - NASDAQ


Stock Charts

FinViz View SGEN Stock Insight & Charts - FinViz.com StockCharts View SGEN Investment Charts - StockCharts.com
BarChart View SGEN Stock Overview & Charts - BarChart Trading View View SGEN User Generated Charts - Trading View




Latest Financial News for SGEN


Blog Exposure - Seattle Genetics Announces First Patient Dosage in Phase-2 innovaTV 207 Trial for Multiple Solid Tumors
Posted on Monday July 16, 2018

LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want access to our free research report on Seattle Genetics, Inc. (NASDAQ: SGEN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SGEN as the Company's latest news hit the wire. On July 12, 2018, the Company announced the dosing of the first patient in the Phase-2 innovaTV 207 clinical trial evaluating the activity, safety, and tolerability of tisotumab vedotin as a monotherapy in selected solid tumors with high Tissue Factor expression. Active-Investors.com is currently working on the research report for BeyondSpring Inc. (NASDAQ: BYSI), which also belongs to the Healthcare sector as the Company Seattle Genetics.


Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering
Posted on Friday July 13, 2018

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 12) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Arbutus Biopharma ...


Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors
Posted on Thursday July 12, 2018

Seattle Genetics, Inc. (SGEN) today announced dosing of the first patient in the phase 2 innovaTV 207 clinical trial evaluating the activity, safety and tolerability of tisotumab vedotin as monotherapy in selected solid tumors with high Tissue Factor expression. Tissue Factor is overexpressed in a broad range of solid tumors that are associated with a poor prognosis. Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) designed to target the Tissue Factor antigen on the surface of cancer cells and deliver the cell-killing agent monomethyl auristatin E (MMAE) directly inside cancer cells.


Breakfast Technical Briefing on Tetraphase Pharma and Three Other Additional Biotech Stocks
Posted on Thursday July 12, 2018

LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on TTPH sign up now at www.wallstequities.com/registration. Companies in the Biotechnology industry primarily use living organisms or molecular and cellular techniques to provide chemicals, food, and services that meet human needs.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.